pneumonia
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1) Age >= 18 y 2) Clinical suspicion of a new episode of acute respiratory tract infection 3) The presence of a new or increased infiltrate on chest radiography or computed tomography (CT) or a positive SARS-CoV-2 PCR on nasopharyngeal swab within 14 days prior to admission 4) Presence of two or more diagnostic clinical criteria: - Cough - Production of purulent sputum or a change in the character of sputum - Temperature >38°C or 10×109 white cells per liter or >15% bands) - C-reactive protein level of more than 3 times the upper limit of the normal range - Dyspnea, tachypnea, or hypoxemia
Exclusion criteria
Exclusion criteria: 1) No informed consent is provided by patient 2) Patients who had recently been hospitalized (for >48 hours in the previous 2 weeks) or who resided in long-term care facilities 3) Patients with a colostomy 4) Patient is enrolled in an interventional clinical study of an anti-infective or immunomodulatory therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main parameters of this study will be the alterations in leukocyte DNA methylation and the composition and function of the intestinal and nasopharyngeal microbiota in patients with CAP. These data will be associated with several clinical parameters, including, but not limited to: • Patient demographics and medical history, at enrolment • Date of hospital admission and discharge, transfer or death • Date of high care unit/intensive care unit admission and discharge, transfer or death, if applicable • Clinical outcome: hospital discharge, transfer or in-hospital death • Mortality at day 90 | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary it will be evaluated whether microbiome derived signals are of influence in differences found in methylation in these study groups. | — |
Countries
Netherlands
Outcome results
None listed